Dec 27, 2023 · In a first experimental system, we titrated the FMC63-scFv on the human CD19 + leukemia model cell line NALM6 using various incubation times, as well as different conditions …

Dec 1, 2020 · Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened …

Four out of six FDA-approved CAR T cell therapies are directed against CD19 and all of those are based on an scFv derived from the murine CD19-specific monoclonal antibody FMC6311,12. …

Apr 22, 2022 · We report cryo-EM structures of CD19 antigen with the binder FMC63, which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, and Breyanzi), …

Apr 22, 2019 · The second-generation anti-CD19 CAR prototype (CD19-BBz), bearing FMC63 single-chain variant fragment (scFv) together with intracellular 4-1BB co-stimulatory and CD3ζ …

Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened several known …

Dec 27, 2023 · The majority of approved CAR T cell products are based on the FMC63-scFv directed against CD19. Surprisingly, although antigen binding affinity is a major determinant …

Dec 1, 2024 · Here, we conducted in-silico structural modelling of an FMC63-based anti-CD19 single-chain variable fragment (scFv) with and without a c-Myc peptide tag added to the N …

Jan 17, 2022 · The previously approved CD19-CAR T products are based on murine-derived scFv (FMC63) that is fused to second-generation CAR [CD28ζ (6, 8) or 4-1BBζ (2, 7)]. In …

The FMC63-28Z CAR consists of an anti-CD19 scFv that was derived from the FMC63 mouse hybridoma 39, a portion of the human CD28 molecule, and the intracellular component of the …